Home » Topics » BioWorld Science, Nephrology

BioWorld Science, Nephrology
RSS

Promising results reported from phase IIa trial of UISH-001

Nov. 8, 2012

Votubia obtains European approval for TSC-associated renal angiomyolipoma

Nov. 6, 2012

Keryx Biopharmaceuticals commences phase II study of Zerenex

Nov. 5, 2012

BAX B-01 shows promise in model of proliferative nephritis

Nov. 5, 2012

European Commission approves Cialis in new indication

Oct. 31, 2012

Dosing commences in phase Ib/IIa study of KD-020

Oct. 29, 2012

Astellas Pharma launches Myrbetriq in U.S.

Oct. 23, 2012

Mirabegron recommended for European approval

Oct. 22, 2012

New data on onabotulinumtoxinA reveals benefits on patient-reported outcomes

Oct. 22, 2012

Ono Pharmaceutical designs novel E-NPP 2 inhibitors

Oct. 22, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 14, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Alzheimer’s, beyond the brain
BioWorld
Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...